<DOC>
	<DOCNO>NCT00940875</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety sequential treatment Tarceva gemcitabine , gemcitabine monotherapy , first line treatment elderly patient , patient ECOG performance status 2 , advance non-small cell lung cancer.Patients randomize receive either sequential gemcitabine 1250mg/m2/day day 1 8 + Tarceva 150mg po day 15-28 4 week cycle , gemcitabine monotherapy 1000mg/m2/day day 1 , 8 15 4 week cycle . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Sequential Combination With Gemcitabine First Line Therapy Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =70 year age ECOG PS 2 ; advance ( stage IIIB IV ) nonsmall cell lung cancer ; prior systemic chemotherapy advance NSCLC prior treatment HERaxis target drug . active brain metastasis spinal cord suppression ; unstable systemic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>